O	0	9	Screening
O	10	13	for
B-Disease	14	22	diabetic
I-Disease	23	34	retinopathy
O	35	39	with
O	40	42	or
O	43	50	without
O	51	52	a
O	53	62	copayment
O	63	65	in
O	66	67	a
O	68	78	randomized
O	79	89	controlled
O	90	95	trial
O	95	96	:
O	97	106	influence
O	107	109	of
O	110	113	the
O	114	121	inverse
O	122	126	care
O	127	130	law
O	130	131	.

O	133	135	To
O	136	143	examine
O	144	151	whether
O	152	155	the
O	156	163	inverse
O	164	168	care
O	169	172	law
O	173	181	operates
O	182	184	in
O	185	186	a
O	187	196	screening
O	197	204	program
O	205	208	for
B-Disease	209	217	diabetic
I-Disease	218	229	retinopathy
O	230	231	(
B-Disease	231	233	DR
O	233	234	)
O	235	240	based
O	241	243	on
O	244	247	fee
O	248	251	for
O	252	259	service
O	260	262	in
B-Characteristic	263	267	Hong
I-Characteristic	268	272	Kong
O	272	273	.

O	274	284	Randomized
O	285	295	controlled
O	296	301	trial
O	301	302	.

O	303	306	All
O	307	312	those
O	313	317	with
B-Disease	318	322	type
I-Disease	323	324	1
I-Disease	325	327	or
I-Disease	328	329	2
I-Disease	330	338	diabetes
O	339	343	from
O	344	345	2
O	346	353	clinics
O	354	358	were
O	359	368	recruited
O	368	369	.

B-Disease	370	378	Diabetic
I-Disease	379	390	retinopathy
O	391	400	screening
O	401	405	with
O	406	407	a
O	408	413	small
O	414	423	copayment
O	424	430	versus
O	431	435	free
O	436	442	access
O	443	445	in
O	446	447	a
O	448	456	publicly
O	457	463	funded
O	464	470	family
O	471	479	medicine
O	480	487	service
O	487	488	.

O	489	495	Uptake
O	496	498	of
O	499	508	screening
O	509	512	and
O	513	521	severity
O	522	524	of
B-Disease	525	527	DR
O	528	536	detected
O	536	537	.

O	538	549	Association
O	550	557	between
O	558	563	these
O	564	571	outcome
O	572	581	variables
O	582	585	and
O	586	597	independent
O	598	607	variables
O	608	612	were
O	613	623	determined
O	624	629	using
O	630	642	multivariate
O	643	651	logistic
O	652	662	regression
O	663	669	models
O	670	673	and
O	674	682	reported
O	683	685	as
O	686	690	odds
O	691	697	ratios
O	698	699	(
O	699	702	ORs
O	702	703	)
O	703	704	.

O	705	710	After
O	711	724	randomization
O	724	725	,
O	726	730	1387
O	731	739	subjects
O	740	742	in
O	743	746	the
O	747	751	free
O	752	757	group
O	758	761	and
O	762	766	1379
O	767	775	subjects
O	776	778	in
O	779	782	the
O	783	786	pay
O	787	792	group
O	793	797	were
O	798	806	eligible
O	807	810	for
O	811	820	screening
O	820	821	,
O	822	825	and
O	826	828	94
O	828	829	.
O	829	830	9
O	830	831	%
O	832	833	(
O	833	837	1316
O	837	838	/
O	838	842	1387
O	842	843	)
O	844	847	and
O	848	850	92
O	850	851	.
O	851	852	6
O	852	853	%
O	854	855	(
O	855	859	1277
O	859	860	/
O	860	864	1379
O	864	865	)
O	865	866	,
O	867	879	respectively
O	879	880	,
O	881	887	agreed
O	888	890	to
O	891	902	participate
O	903	905	in
O	906	909	the
O	910	915	study
O	915	916	.

O	917	920	The
O	921	926	offer
O	927	929	of
O	930	939	screening
O	940	943	was
O	944	952	accepted
O	953	955	by
O	956	958	94
O	958	959	.
O	959	960	8
O	960	961	%
O	962	963	(
O	963	967	1247
O	967	968	/
O	968	972	1316
O	972	973	)
O	974	976	in
O	977	980	the
O	981	985	free
O	986	991	group
O	992	995	and
O	996	998	91
O	998	999	.
O	999	1000	2
O	1000	1001	%
O	1002	1003	(
O	1003	1007	1164
O	1007	1008	/
O	1008	1012	1277
O	1012	1013	)
O	1014	1016	in
O	1017	1020	the
O	1021	1024	pay
O	1025	1030	group
O	1030	1031	,
O	1032	1035	and
O	1036	1039	the
O	1040	1045	final
O	1046	1052	uptake
O	1053	1059	ratios
O	1060	1064	were
O	1065	1067	88
O	1067	1068	.
O	1068	1069	5
O	1069	1070	%
O	1071	1072	(
O	1072	1076	1165
O	1076	1077	/
O	1077	1081	1316
O	1081	1082	)
O	1083	1086	and
O	1087	1089	82
O	1089	1090	.
O	1090	1091	4
O	1091	1092	%
O	1093	1094	(
O	1094	1098	1052
O	1098	1099	/
O	1099	1103	1277
O	1103	1104	)
O	1104	1105	,
O	1106	1118	respectively
O	1119	1120	(
O	1120	1127	Pearson
O	1128	1131	chi
O	1132	1133	=
O	1134	1136	19
O	1136	1137	.
O	1137	1139	74
O	1139	1140	,
O	1141	1142	P
O	1143	1144	<
O	1145	1146	0
O	1146	1147	.
O	1147	1150	001
O	1150	1151	)
O	1151	1152	.

O	1153	1158	Being
O	1159	1161	in
O	1162	1165	the
O	1166	1169	pay
O	1170	1175	group
O	1176	1179	was
O	1180	1190	associated
O	1191	1195	with
O	1196	1197	a
O	1198	1203	lower
O	1204	1210	uptake
O	1211	1213	of
O	1214	1223	screening
O	1224	1228	than
O	1229	1234	being
O	1235	1237	in
O	1238	1241	the
O	1242	1246	free
O	1247	1252	group
O	1253	1254	(
O	1254	1256	OR
O	1256	1257	,
O	1258	1259	0
O	1259	1260	.
O	1260	1262	59
O	1262	1263	;
O	1264	1274	confidence
O	1275	1283	interval
O	1284	1285	[
O	1285	1287	CI
O	1287	1288	]
O	1288	1289	,
O	1290	1291	0
O	1291	1292	.
O	1292	1294	47
O	1294	1295	-
O	1295	1296	0
O	1296	1297	.
O	1297	1299	74
O	1299	1300	)
O	1301	1304	and
O	1305	1306	a
O	1307	1312	lower
O	1313	1322	detection
O	1323	1327	rate
O	1328	1330	of
B-Disease	1331	1333	DR
O	1334	1335	(
O	1335	1337	OR
O	1337	1338	,
O	1339	1340	0
O	1340	1341	.
O	1341	1343	73
O	1343	1344	;
O	1345	1347	CI
O	1347	1348	,
O	1349	1350	0
O	1350	1351	.
O	1351	1353	60
O	1353	1354	-
O	1354	1355	0
O	1355	1356	.
O	1356	1358	90
O	1358	1359	)
O	1360	1365	after
O	1366	1376	adjustment
O	1377	1380	for
O	1381	1390	potential
O	1391	1402	confounding
O	1403	1410	factors
O	1410	1411	.

O	1412	1420	Subjects
O	1421	1425	with
B-Characteristic	1426	1432	higher
I-Characteristic	1433	1446	socioeconomic
I-Characteristic	1447	1453	status
O	1454	1458	were
O	1459	1463	more
O	1464	1470	likely
O	1471	1473	to
O	1474	1480	attend
O	1481	1490	screening
O	1491	1494	and
O	1495	1498	had
O	1499	1500	a
O	1501	1506	lower
O	1507	1517	prevalence
O	1518	1520	of
B-Disease	1521	1523	DR
O	1524	1532	detected
O	1532	1533	.

O	1534	1537	The
O	1538	1545	inverse
O	1546	1550	care
O	1551	1554	law
O	1555	1560	seems
O	1561	1563	to
O	1564	1571	operate
O	1572	1574	in
O	1575	1576	a
O	1577	1587	preventive
O	1588	1600	intervention
O	1601	1605	when
O	1606	1607	a
O	1608	1618	relatively
O	1619	1624	small
O	1625	1634	copayment
O	1635	1637	is
O	1638	1645	applied
O	1645	1646	.

O	1647	1652	There
O	1653	1655	is
O	1656	1657	a
O	1658	1662	case
O	1663	1666	for
O	1667	1673	making
O	1674	1683	effective
O	1684	1694	preventive
O	1695	1703	services
O	1704	1708	free
O	1709	1711	of
O	1712	1718	charge
O	1718	1719	.

O	1720	1723	The
O	1724	1730	author
O	1730	1731	(
O	1731	1732	s
O	1732	1733	)
O	1734	1738	have
O	1739	1741	no
O	1742	1753	proprietary
O	1754	1756	or
O	1757	1767	commercial
O	1768	1776	interest
O	1777	1779	in
O	1780	1783	any
O	1784	1793	materials
O	1794	1803	discussed
O	1804	1806	in
O	1807	1811	this
O	1812	1819	article
O	1819	1820	.
